Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum

Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · see citing works

Robust Locally Weighted Regression and Smoothing Scatterplots

Cleveland, W. S. (1979) · Journal of the American Statistical Association · doi:10.1080/01621459.1979.10481038 · Cited by 11,594 · see citing works

NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · see citing works

Neuroinflammation in Alzheimer's disease

Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · see citing works

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · see citing works

Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity

DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376 · see citing works

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049 · see citing works

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864 · see citing works

Biomarker Modeling of Alzheimer’s Disease

Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002 · see citing works

TDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease

Amador‐Ortiz, C., Lin, W., Ahmed, Z., Personett, D., Davies, P., Duara, R., Graff‐Radford, N. R., Hutton, M. L., & Dickson, D. W. (2007) · Annals of Neurology · doi:10.1002/ana.21154 · Cited by 916 · see citing works

CSF biomarkers of Alzheimer's disease concord with amyloid‐β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts

Hansson, O., Seibyl, J., Stomrud, E., Zetterberg, H., Trojanowski, J. Q., Bittner, T., Lifke, V., Corradini, V., Eichenlaub, U., Batrla, R., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.010 · Cited by 808 · see citing works

Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry

Hamilton, R. L. (2000) · Brain Pathology · doi:10.1111/j.1750-3639.2000.tb00269.x · Cited by 754 · see citing works

Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease

Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L. A., McKeel, D. W., & Morris, J. C. (2001) · Neurology · doi:10.1212/wnl.56.1.127 · Cited by 720 · see citing works

Introduction to signal processing

Popescu, T. D. (1996) · Control Engineering Practice · doi:10.1016/s0967-0661(96)90009-x · Cited by 684 · see citing works

Neuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease

Price, J. L., Ko, A. I., Wade, M. J., Tsou, S. K., McKeel, D. W., & Morris, J. C. (2001) · Archives of Neurology · doi:10.1001/archneur.58.9.1395 · Cited by 596 · see citing works

Lewy Bodies Contain Altered α-Synuclein in Brains of Many Familial Alzheimer's Disease Patients with Mutations in Presenilin and Amyloid Precursor Protein Genes

Lippa, C. F., Fujiwara, H., Mann, D. M. A., Giasson, B., Baba, M., Schmidt, M. L., Nee, L. E., O'Connell, B., Pollen, D. A., St. George-Hyslop, P., et al. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65722-7 · Cited by 533 · see citing works

Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease

Tokuda, T., Qureshi, M. M., Ardah, M. T., Varghese, S., Shehab, S. A. S., Kasai, T., Ishigami, N., Tamaoka, A., Nakagawa, M., & El‐Agnaf, O. M. A. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fd613b · Cited by 526 · see citing works

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers

Suárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522 · see citing works

Synaptic degeneration in Alzheimer's disease

Arendt, T. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0536-x · Cited by 517 · see citing works

YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease

Craig-Schapiro, R., Perrin, R. J., Roe, C. M., Xiong, C., Carter, D., Cairns, N. J., Mintun, M. A., Peskind, E. R., Li, G., Galasko, D. R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.025 · Cited by 504 · see citing works

Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression

Zetterberg, H., Skillbäck, T., Mattsson, N., Trojanowski, J. Q., Portelius, E., Shaw, L. M., Weiner, M. W., Blennow, K., & Initiative, F. T. A. D. N. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3037 · Cited by 487 · see citing works

Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease

Fagan, A. M., Xiong, C., Jasielec, M. S., Bateman, R. J., Goate, A. M., Benzinger, T. L. S., Ghetti, B., Martins, R. N., Masters, C. L., Mayeux, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007901 · Cited by 434 · see citing works

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

Palmqvist, S., Mattsson, N., Hansson, O., & Initiative, F. T. A. D. N. (2016) · Brain · doi:10.1093/brain/aww015 · Cited by 400 · see citing works

Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease

Benzinger, T. L. S., Blazey, T., Jack, C. R., Koeppe, R. A., Su, Y., Xiong, C., Raichle, M. E., Snyder, A. Z., Ances, B. M., Bateman, R. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317918110 · Cited by 391 · see citing works

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

Palmqvist, S., Insel, P. S., Stomrud, E., Janelidze, S., Zetterberg, H., Brix, B., Eichenlaub, U., Dage, J. L., Chai, X., Blennow, K., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201911170 · Cited by 353 · see citing works

Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology

Initiative, F. T. A. D. N., Suárez-Calvet, M., Morenas-Rodríguez, E., Kleinberger, G., Schlepckow, K., Araque Caballero, M. Á., Franzmeier, N., Capell, A., Fellerer, K., Nuscher, B., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0301-5 · Cited by 347 · see citing works

Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status

Piccio, L., Deming, Y., Del-Águila, J. L., Ghezzi, L., Holtzman, D. M., Fagan, A. M., Fenoglio, C., Galimberti, D., Borroni, B., & Cruchaga, C. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1533-5 · Cited by 337 · see citing works

Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50–95 years: a cross-sectional study

Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Knopman, D. S., Lowe, V., Vemuri, P., Mielke, M. M., Roberts, R. O., Machulda, M. M., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30077-7 · Cited by 333 · see citing works

Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease

McDade, E., Wang, G., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Holtzman, D. M., Cairns, N. J., Goate, A. M., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006277 · Cited by 314 · see citing works

Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease

Heslegrave, A., Heywood, W., Paterson, R., Magdalinou, N., Svensson, J., Johansson, P., Öhrfelt, A., Blennow, K., Hardy, J., Schott, J., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0071-x · Cited by 303 · see citing works

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Mattsson, N., Insel, P. S., Palmqvist, S., Portelius, E., Zetterberg, H., Weiner, M. W., Blennow, K., Hansson, O., & Initiative, T. A. D. N. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606540 · Cited by 293 · see citing works

Phosphorylated α-Synuclein in Parkinson’s Disease

Wang, Y., Shi, M. Y., Chung, K. A., Zabetian, C. P., Leverenz, J. B., Berg, D., Srulijes, K., Trojanowski, J. Q., Lee, V. M. ‐., Siderowf, A. D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002566 · Cited by 281 · see citing works

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease

Majbour, N. K., Vaikath, N. N., van Dijk, K. D., Ardah, M. T., Varghese, S., Vesterager, L. B., Montezinho, L. P., Poole, S., Safieh‐Garabedian, B., Tokuda, T., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0072-9 · Cited by 279 · see citing works

Early changes in CSF sTREM2 in dominantly inherited Alzheimer’s disease occur after amyloid deposition and neuronal injury

Suárez-Calvet, M., Araque Caballero, M. Á., Kleinberger, G., Bateman, R. J., Fagan, A. M., Morris, J. C., Levin, J., Danek, A., Ewers, M., Haass, C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1767 · Cited by 272 · see citing works

CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival

Skillbäck, T., Farahmand, B., Bartlett, J. W., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., Religa, D., Wimo, A., Winblad, B., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001015 · Cited by 263 · see citing works

Increased CSF neurogranin concentration is specific to Alzheimer disease

Wellington, H., Paterson, R. W., Portelius, E., Törnqvist, U., Magdalinou, N., Fox, N. C., Blennow, K., Schott, J. M., & Zetterberg, H. (2016) · Neurology · doi:10.1212/wnl.0000000000002423 · Cited by 232 · see citing works

Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease

Tarawneh, R. M., D’Angelo, G., Crimmins, D. L., Herries, E. M., Griest, T. A., Fagan, A. M., Zipfel, G. J., Ladenson, J. H., Morris, J. C., & Holtzman, D. M. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0086 · Cited by 219 · see citing works

Neurofilament protein in cerebrospinal fluid: A marker of white matter changes

Sjögren, M., Blomberg, M., Jonsson, M., Wahlund, L. ‐., Edman, Å., Lind, K., Rosengren, L., Blennow, K., & Wallin, A. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1242 · Cited by 209 · see citing works

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

Hansson, O., Hall, S., Öhrfelt, A., Zetterberg, H., Blennow, K., Minthon, L., Nägga, K., Londos, E., Varghese, S., Majbour, N. K., et al. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt255 · Cited by 208 · see citing works

The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease

Molinuevo, J. L., Gramunt, N., Gispert, J. D., Fauria, K., Esteller, M., Minguillón, C., Sánchez‐Benavides, G., Huesa, G., Morán, S., Dal‐Ré, R., et al. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.02.003 · Cited by 177 · see citing works

Associations Between Biomarkers and Age in the Presenilin 1 E280A Autosomal Dominant Alzheimer Disease Kindred: A Cross-sectional Study

Fleisher, A. S., Chen, K., Quiroz, Y. T., Jakimovich, L. J., Gutierrez Gomez, M., Langois, C. M., Langbaum, J. B. S., Roontiva, A., Thiyyagura, P., Lee, W., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.3314 · Cited by 177 · see citing works

Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease

Alcolea, D., Martínez-Lage, P., Sánchez-Juan, P., Olazarán, J., Antúnez, C., Izagirre, A., Ecay-Torres, M., Estanga, A., Clerigué, M., Guisasola, M. C., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001859 · Cited by 163 · see citing works

Early astrocytosis in autosomal dominant Alzheimer’s disease measured in vivo by multi-tracer positron emission tomography

Schöll, M., Carter, S. F., Westman, E., Rodriguez‐Vieitez, E., Almkvist, O., Þórðardóttir, S., Wall, A. E., Graff, C., Långström, B., & Nordberg, A. K. (2015) · Scientific Reports · doi:10.1038/srep16404 · Cited by 146 · see citing works

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Henjum, K., Almdahl, I. S., Årskog, V., Minthon, L., Hansson, O., Fladby, T., & Nilsson, L. N. G. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0182-1 · Cited by 141 · see citing works

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

Lleó, A., Alcolea, D. A., Martínez‐Lage, P., Scheltens, P., Parnetti, L., Poirier, J., Simonsen, A. H., Verbeek, M. M., Rosa‐Neto, P., Slot, R. E. R., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.01.015 · Cited by 127 · see citing works

Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum

Bos, I., Vos, S. J. B., Verhey, F. R. J., Scheltens, P., Teunissen, C. E., Engelborghs, S., Sleegers, K., Frisoni, G. B., Blin, O. J., Richardson, J. C., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.01.004 · Cited by 122 · see citing works

Relationship Between β-Secretase, Inflammation and Core Cerebrospinal Fluid Biomarkers for Alzheimer's Disease

Alcolea, D. A., Carmona‐Iragui, M., Suárez‐Calvet, M., Sánchez‐Saudinós, M. B., Sala, I., Antón‐Aguirre, S., Blesa, R., Clarimón, J., Fortea, J., & Lleó, A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140240 · Cited by 112 · see citing works

Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease

Vlassenko, A. G., McCue, L., Jasielec, M. S., Su, Y., Gordon, B. A., Xiong, C., Holtzman, D. M., Benzinger, T. L. S., Morris, J. C., & Fagan, A. M. (2016) · Annals of Neurology · doi:10.1002/ana.24719 · Cited by 106 · see citing works

Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease

Schindler, S. E., Li, Y., Todd, K. W., Herries, E. M., Henson, R. L., Gray, J. D., Wang, G., Graham, D. L., Shaw, L. M., Trojanowski, J. Q., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.12.019 · Cited by 101 · see citing works

CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum

Illán‐Gala, I., Alcolea, D. A., Montal, V., Dols‐Icardo, O., Muñoz, L., de Luna, N., Turón‐Sans, J., Cortés‐Vicente, E., Sánchez‐Saudinós, M. B., Subirana, A., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006383 · Cited by 85 · see citing works

Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer’s disease

Morenas‐Rodríguez, E., Alcolea, D. A., Suárez‐Calvet, M., Muñoz, L., Vilaplana, E., Sala, I., Subirana, A., Querol‐Vilaseca, M., Carmona‐Iragui, M., Illán‐Gala, I., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-44173-8 · Cited by 58 · see citing works

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.

Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02275-6 · Cited by 719 · see citing works

Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum.

Benedet, A. L., Milà-Alomà, M., Vrillon, A., Ashton, N. J., Pascoal, T. A., Lussier, F., Karikari, T. K., Hourregue, C., Cognat, E., Dumurgier, J., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3671 · Cited by 638 · see citing works

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected

Suárez‐Calvet, M., Karikari, T. K., Ashton, N. J., Lantero Rodríguez, J., Milà‐Alomà, M., Gispert, J. D., Salvadó, G., Minguillon, C., Fauria, K., Shekari, M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012921 · Cited by 401 · see citing works

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Milà-Alomà, M., Ashton, N. J., Shekari, M., Salvadó, G., Ortiz-Romero, P., Montoliu-Gaya, L., Benedet, A. L., Karikari, T. K., Lantero-Rodriguez, J., Vanmechelen, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01925-w · Cited by 353 · see citing works

Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis

Liss, J. L., Seleri Assunção, S., Cummings, J., Atri, A., Geldmacher, D. S., Candela, S. F., Devanand, D. P., Fillit, H. M., Susman, J., Mintzer, J., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13244 · Cited by 312 · see citing works

Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads

Salvadó, G., Ossenkoppele, R., Ashton, N. J., Beach, T. G., Serrano, G. E., Reiman, E. M., Zetterberg, H., Mattsson‐Carlgren, N., Janelidze, S., Blennow, K., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202217123 · Cited by 205 · see citing works

Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5–90 years

Simrén, J., Andréasson, U., Gobom, J., Suárez‐Calvet, M., Borroni, B., Gillberg, C., Nyberg, L. H., Ghidoni, R., Fernell, E., Johnson, M., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac174 · Cited by 196 · see citing works

Blood-Based Biomarkers for Alzheimer’s Disease Diagnosis and Progression: An Overview

Varesi, A., Carrara, A., Pires, V. G., Floris, V., Pierella, E., Savioli, G., Prasad, S., Esposito, C., Ricevuti, G., Chirumbolo, S., et al. (2022) · Cells · doi:10.3390/cells11081367 · Cited by 142 · see citing works

Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease

Ferrari-Souza, J., Ferreira, P., Bellaver, B., Tissot, C., Wang, Y., Leffa, D., Brum, W., Benedet, A., Ashton, N., de Bastiani, M. D., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01716-2 · Cited by 126 · see citing works

An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum

Hulle, C. V., Jonaitis, E. M., Betthauser, T. J., Batrla, R., Wild, N., Kollmorgen, G., Andréasson, U., Okonkwo, O. C., Bendlin, B. B., Asthana, S., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12204 · Cited by 137 · see citing works

Astrocyte biomarkers GFAP and YKL‐40 mediate early Alzheimer's disease progression

Pelkmans, W., Shekari, M., Brugulat‐Serrat, A., Sánchez‐Benavides, G., Minguillón, C., Fauria, K., Molinuevo, J. L., Grau‐Rivera, O., González Escalante, A., Kollmorgen, G., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13450 · Cited by 122 · see citing works

Systematic Assessment of 10 Biomarker Candidates Focusing on α‐Synuclein‐Related Disorders

Schulz, I., Kruse, N., Gera, R. G., Kremer, T., Cedarbaum, J. M., Barbour, R., Zago, W. M., Schade, S., Otte, B., Bartl, M., et al. (2021) · Movement Disorders · doi:10.1002/mds.28738 · Cited by 117 · see citing works

Blood Biomarkers in Neurodegenerative Diseases

Alcolea, D. A., Beeri, M. S., Rojas, J. C., Gardner, R. C., & Lleó, A. (2023) · Neurology · doi:10.1212/wnl.0000000000207193 · Cited by 121 · see citing works

The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease

Jung, Y., & Damoiseaux, J. S. (2023) · Brain · doi:10.1093/brain/awad267 · Cited by 117 · see citing works

CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET

Milà‐Alomà, M., Brinkmalm, A., Ashton, N. J., Kvartsberg, H., Shekari, M., Operto, G., Salvadó, G., Falcón, C., Gispert, J. D., Vilor‐Tejedor, N., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012853 · Cited by 117 · see citing works

A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease

for the REVERSE-SD Study Investigators, Prins, N. D., Harrison, J., Chu, H., Blackburn, K., Alam, J. J., & Scheltens, P. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00843-2 · Cited by 110 · see citing works

Brain Shape Changes Associated With Cerebral Atrophy in Healthy Aging and Alzheimer’s Disease

Blinkouskaya, Y., & Weickenmeier, J. (2021) · Frontiers in Mechanical Engineering · doi:10.3389/fmech.2021.705653 · Cited by 109 · see citing works

An overview of the relationship between inflammation and cognitive function in humans, molecular pathways and the impact of nutraceuticals

Mekhora, C., Lamport, D. J., & Spencer, J. P. E. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105900 · Cited by 103 · see citing works

Associations between air pollution and biomarkers of Alzheimer’s disease in cognitively unimpaired individuals

Alemany, S., Crous‐Bou, M., Vilor‐Tejedor, N., Milà‐Alomà, M., Suárez‐Calvet, M., Salvadó, G., Cirach, M., Arenaza‐Urquijo, E. M., Sánchez‐Benavides, G., Grau‐Rivera, O., et al. (2021) · Environment International · doi:10.1016/j.envint.2021.106864 · Cited by 101 · see citing works

The dynamics of plasma biomarkers across the Alzheimer’s continuum

Guo, Y., Shen, X., Wang, H.-F., Chen, S.-D., Zhang, Y.-R., Chen, S., Cui, M., Cheng, W., Dong, Q., Ma, T., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01174-0 · Cited by 90 · see citing works

Plasma Glial Fibrillary Acidic Protein in the Alzheimer Disease Continuum: Relationship to Other Biomarkers, Differential Diagnosis, and Prediction of Clinical Progression

Shen, X., Huang, S., Cui, M., Zhao, Q., Guo, Y., Huang, Y., Zhang, W., Ma, Y., Chen, S.-D., Zhang, Y.-R., et al. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad018 · Cited by 96 · see citing works

Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia

Zhu, N., Santos-Santos, M., Illán-Gala, I., Montal, V., Estellés, T., Barroeta, I., Altuna, M., Arranz, J., Muñoz, L., Belbin, O., et al. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00275-w · Cited by 86 · see citing works

A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer's dementia: China Aging and Neurodegenerative Initiative (CANDI) study

Gao, F., Lv, X., Dai, L., Wang, Q., Wang, P., Cheng, Z., Xie, Q., Ni, M., Wu, Y., Chai, X., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12700 · Cited by 86 · see citing works

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease

Nilsson, J., Gobom, J., Sjödin, S., Brinkmalm, G., Ashton, N. J., Svensson, J., Johansson, P., Portelius, E., Zetterberg, H., Blennow, K., et al. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12179 · Cited by 82 · see citing works

Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ‐PET, neurodegeneration, and cognition

Chatterjee, P., Vermunt, L., Gordon, B. A., Pedrini, S., Boonkamp, L., Armstrong, N. J., Xiong, C., Singh, A. K., Li, Y., Sohrabi, H. R., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12879 · Cited by 89 · see citing works

Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics

Arslan, B., Zetterberg, H., & Ashton, N. J. (2024) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-1434 · Cited by 88 · see citing works

State‐of‐the‐art of lumbar puncture and its place in the journey of patients with Alzheimer's disease

Hampel, H., Shaw, L. M., Aisen, P., Chen, C., Lleó, A., Iwatsubo, T., Iwata, A., Yamada, M., Ikeuchi, T., Jia, J., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12372 · Cited by 77 · see citing works

Emerging blood exosome-based biomarkers for preclinical and clinical Alzheimer’s disease: a meta-analysis and systematic review

Chen, L., Liu, W., Lin, H., Lin, M., Yu, Y., Liu, H., Dai, Y., Chen, L.-W., Jia, W., He, X., et al. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335832 · Cited by 74 · see citing works

Application of CRISPR/Cas9 in Alzheimer’s Disease

Lu, L., Xi, Y., Cai, Y., Sun, M., & Yang, H. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.803894 · Cited by 78 · see citing works

Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Sensitivity, Specificity and Potential for Clinical Use

d’Abramo, C., D'adamio, L., & Giliberto, L. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030116 · Cited by 68 · see citing works

Biological brain age prediction using machine learning on structural neuroimaging data: Multi-cohort validation against biomarkers of Alzheimer’s disease and neurodegeneration stratified by sex

Cumplido‐Mayoral, I., García-Prat, M., Operto, G., Falcón, C., Shekari, M., Cacciaglia, R., Milà‐Alomà, M., Lorenzini, L., Ingala, S., Wink, A. M., et al. (2023) · eLife · doi:10.7554/elife.81067 · Cited by 68 · see citing works

Fluid-based biomarkers for neurodegenerative diseases

Cao, Y., Xu, Y., Cao, M., Chen, N., Zeng, Q., Lai, M. K. P., Fan, D., Sethi, G., & Cao, Y. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102739 · Cited by 65 · see citing works

From Recognition to Remedy: The Significance of Biomarkers in Neurodegenerative Disease Pathology

Toader, C., Dobrin, N., Brehar, F.-M., Popa, C., Covache-Busuioc, R.-A., Glavan, L.-A., Costin, H. P., Bratu, B.-G., Corlatescu, A.-D., Popa, A. A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216119 · Cited by 61 · see citing works

Neuropathological and Biomarker Findings in Parkinson’s Disease and Alzheimer’s Disease: From Protein Aggregates to Synaptic Dysfunction

Compta, Y., & Révész, T. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202323 · Cited by 61 · see citing works

Large-scale proteomic analyses of incident Parkinson’s disease reveal new pathophysiological insights and potential biomarkers

Gan, Y., Ma, L., Zhang, Y., You, J., Guo, Y. X., He, Y., Wang, L., He, X.-Y., Li, Y., Dong, Q., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00818-0 · Cited by 59 · see citing works

Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer’s continuum

Vilor‐Tejedor, N., Ciampa, I., Operto, G., Falcón, C., Suárez‐Calvet, M., Crous‐Bou, M., Shekari, M., Arenaza‐Urquijo, E. M., Milà‐Alomà, M., Grau‐Rivera, O., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00878-5 · Cited by 59 · see citing works

P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease

Lantero‐Rodriguez, J., Snellman, A., Benedet, A. L., Milà‐Alomà, M., Camporesi, E., Montoliu‐Gaya, L., Ashton, N. J., Vrillon, A., Karikari, T. K., Gispert, J. D., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202115098 · Cited by 54 · see citing works

Aquaporin-4 cerebrospinal fluid levels are higher in neurodegenerative dementia: looking at glymphatic system dysregulation

Arighi, A., Arcaro, M., Fumagalli, G., Carandini, T., Pietroboni, A. M., Sacchi, L., Fenoglio, C., Serpente, M., Sorrentino, F., Isgrò, G., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01077-6 · Cited by 52 · see citing works

Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease

Bartl, M., Dakna, M., Galasko, D. R., Hutten, S. J., Foroud, T., Quan, M., MAREK, K. L., Siderowf, A. D., Franz, J., Trenkwalder, C., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257372 · Cited by 54 · see citing works

Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: a multi-cohort study

Salvadó, G., Larsson, V., Cody, K. A., Cullen, N. C., Jonaitis, E. M., Stomrud, E., Kollmorgen, G., Wild, N., Palmqvist, S., Janelidze, S., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12907 · Cited by 46 · see citing works

The impact of physical exercise on neuroinflammation mechanism in Alzheimer’s disease

Hu, J., Huang, B., & Chen, K. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1444716 · Cited by 52 · see citing works

Brain alterations in the early Alzheimer’s continuum with amyloid-β, tau, glial and neurodegeneration CSF markers

Salvadó, G., Shekari, M., Falcón, C., Operto, G., Milà‐Alomà, M., Sánchez‐Benavides, G., Cacciaglia, R., Arenaza‐Urquijo, E. M., Niñerola‐Baizán, A., Perissinotti, A., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac134 · Cited by 45 · see citing works

Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals

Öhrfelt, A., Benedet, A. L., Ashton, N. J., Kvartsberg, H., Vandijck, M. L. J., Weiner, M. W., Trojanowski, J. Q., Shaw, L. M. J., Zetterberg, H., Blennow, K., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201417 · Cited by 44 · see citing works

Fluid Biomarkers for the Diagnosis of Neurodegenerative Diseases

Luebke, M., Parulekar, M., & Thomas, F. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100062 · Cited by 33 · see citing works

Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers

Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 47 · see citing works

Alzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint

Alawode, D. O. T., Fox, N. C., Zetterberg, H., & Heslegrave, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.837390 · Cited by 40 · see citing works

Exploring the Role of Reactive Oxygen Species in the Pathogenesis and Pathophysiology of Alzheimer’s and Parkinson’s Disease and the Efficacy of Antioxidant Treatment

Gogna, T., Housden, B. E., & Houldsworth, A. (2024) · Antioxidants · doi:10.3390/antiox13091138 · Cited by 43 · see citing works

Large-scale plasma proteomic profiling unveils diagnostic biomarkers and pathways for Alzheimer’s disease

Heo, G., Xu, Y., Wang, E., Ali, M., Oh, H. S., Losada, P. M., Anastasi, F., Escalante, A. G., Puerta, R., Song, S., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00872-8 · Cited by 39 · see citing works

Microglia modulate Aβ-dependent astrocyte reactivity in Alzheimer’s disease

Ferrari-Souza, J. P., Povala, G., Rahmouni, N., Bellaver, B., Ferreira, P., de Bastiani, M. D., Leffa, D., Lussier, F., Aguzzoli, C., Brum, W., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02103-0 · Cited by 37 · see citing works

Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer’s continuum

Salvadó, G., Milà-Alomà, M., Shekari, M., Ashton, N. J., Operto, G., Falcon, C., Cacciaglia, R., Minguillon, C., Fauria, K., Niñerola-Baizán, A., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05897-4 · Cited by 36 · see citing works

PET imaging of reactive astrocytes in neurological disorders

Liu, Y., Jiang, H., Qin, X., Tian, M., & Zhang, H. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05640-5 · Cited by 35 · see citing works

Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer’s disease

Barba, L., Abu‐Rumeileh, S., Bellomo, G., Paoletti, F. P., Halbgebauer, S., Oeckl, P., Steinacker, P., Massa, F., Gaetani, L., Parnetti, L., et al. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-329124 · Cited by 35 · see citing works

Reducing PDK1/Akt Activity: An Effective Therapeutic Target in the Treatment of Alzheimer’s Disease

Yang, S., Du, Y., Zhao, X., Wu, C., & Yu, P. (2022) · Cells · doi:10.3390/cells11111735 · Cited by 36 · see citing works

Elevated blood and cerebrospinal fluid biomarkers of microglial activation and blood‒brain barrier disruption in anti-NMDA receptor encephalitis

Chang, H., Ma, J., Feng, K., Feng, N., Wang, X., Sun, J., Guo, T., Wei, Y., Xu, Y., Wang, H., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02841-7 · Cited by 33 · see citing works

Glial reactivity correlates with synaptic dysfunction across aging and Alzheimer’s disease

Rohden, F., Ferreira, P. C. L., Bellaver, B., Ferrari‐Souza, J. P., Aguzzoli, C. S., Soares, C., Abbas, S., Zalzale, H., Povala, G., Lussier, F. Z., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60806-1 · Cited by 36 · see citing works

Diagnostic performance of plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non‐AD dementias: An international multi‐center study

Doecke, J. D., Bellomo, G., Vermunt, L., Alcolea, D. A., Halbgebauer, S., Veld, S. G. J. G. I. ‘., Mattsson, N., Veverová, K., Fowler, C. J., Boonkamp, L., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14573 · Cited by 41 · see citing works

The role of synaptic biomarkers in the spectrum of neurodegenerative diseases

Mazzucchi, S., Palermo, G., Campese, N., Galgani, A., Vecchia, A. D., Vergallo, A., Siciliano, G., Ceravolo, R., Hampel, H. J., & Baldacci, F. (2020) · Expert Review of Proteomics · doi:10.1080/14789450.2020.1831388 · Cited by 32 · see citing works

Asthma amplifies dementia risk: Evidence from CSF biomarkers and cognitive decline

Nair, A. K., Hulle, C. A. V., Bendlin, B. B., Zetterberg, H., Blennow, K., Wild, N., Kollmorgen, G., Suridjan, I., Busse, W. W., & Rosenkranz, M. A. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12315 · Cited by 30 · see citing works

Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers

Mielke, M. M., Przybelski, S. A., Lesnick, T. G., Kern, S., Zetterberg, H., Blennow, K., Knopman, D. S., Graff‐Radford, J., Petersen, R. C., Jack, C. R., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12239 · Cited by 30 · see citing works

Cerebral amyloid‐β load is associated with neurodegeneration and gliosis: Mediation by p‐tau and interactions with risk factors early in the Alzheimer's continuum

Salvadó, G., Milà‐Alomà, M., Shekari, M., Minguillón, C., Fauria, K., Niñerola‐Baizán, A., Perissinotti, A., Kollmorgen, G., Buckley, C. J., Farrar, G., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12245 · Cited by 28 · see citing works

Neuroinflammation Biomarkers in the AT(N) Framework Across the Alzheimer's Disease Continuum

Bieger, A., Rocha, A., Bellaver, B., Machado, L. S., Ros, L. U. D., Borelli, W. V., Therriault, J., Macedo, A. C., Pascoal, T. A., Gauthier, S. G., et al. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.54 · Cited by 29 · see citing works

Sex/gender effects of glial reactivity on preclinical Alzheimer’s disease pathology

Vila‐Castelar, C., Akinci, M., Palpatzis, E., Dominguez, P. A., Operto, G., Kollmorgen, G., Quijano‐Rubio, C., Blennow, K., Zetterberg, H., Falcón, C., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02753-9 · Cited by 31 · see citing works

Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer’s disease

Grau-Rivera, O., Navalpotro-Gómez, I., Sánchez-Benavides, G., Suárez-Calvet, M., Milà-Alomà, M., Arenaza-Urquijo, E., Salvadó, G., Sala-Vila, A., Shekari, M., González-de-Echávarri, J., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00781-z · Cited by 18 · see citing works

Silver nanoparticles induce iron accumulation-associated cognitive impairment via modulating neuronal ferroptosis

Zhai, X., Yan, W., Liu, S., Tian, L., Zhang, Y., Zhao, Y., Ni, Y., Shen, H., Wang, J., Wan, Z., et al. (2024) · Environmental Pollution · doi:10.1016/j.envpol.2024.123555 · Cited by 25 · see citing works

CSF protein ratios with enhanced potential to reflect Alzheimer’s disease pathology and neurodegeneration

Mravinacová, S., Alanko, V., Bergström, S., Bridel, C., Pijnenburg, Y. A. L., Hagman, G., Kivipelto, M., Teunissen, C. E., Nilsson, P., Matton, A., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00705-z · Cited by 25 · see citing works

Neuroinflammation, cerebrovascular dysfunction and diurnal cortisol biomarkers in a memory clinic cohort: Findings from the Co-STAR study

Daniilidou, M., Holleman, J., Hagman, G., Kåreholt, I., Aspö, M., Brinkmalm, A., Zetterberg, H., Blennow, K., Solomon, A., Kivipelto, M., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03072-x · Cited by 24 · see citing works

Genetic characterization of the ALFA study: Uncovering genetic profiles in the Alzheimer's continuum

Vilor‐Tejedor, N., Genius, P., Rodríguez‐Fernández, B., Minguillón, C., Sadeghi, I., González‐Escalante, A., Crous‐Bou, M., Suárez‐Calvet, M., Grau‐Rivera, O., Brugulat‐Serrat, A., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13537 · Cited by 24 · see citing works

The neutrophil to lymphocyte ratio associates with markers of Alzheimer’s disease pathology in cognitively unimpaired elderly people

Jacobs, T., Jacobson, S. R., Fortea, J., Berger, J. S., Vedvyas, A., Marsh, K., He, T., Gutiérrez‐Jiménez, E., Fillmore, N. R., Gonzalez, M., et al. (2024) · Immunity & Ageing · doi:10.1186/s12979-024-00435-2 · Cited by 26 · see citing works

Large-scale proteomic analyses of incident Alzheimer’s disease reveal new pathophysiological insights and potential therapeutic targets

Zhang, Y., Guo, Y. X., He, Y., You, J., Zhang, Y., Wang, L., Chen, S., He, X., Yang, L., Huang, Y., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02840-x · Cited by 22 · see citing works

A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer’s disease

González‐Escalante, A., Milà‐Alomà, M., Brum, W. S., Ashton, N. J., Ortiz-Romero, P. L., Shekari, M., del Campo, M., Anastasi, F., Quijano‐Rubio, C., Kollmorgen, G., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105741 · Cited by 24 · see citing works

Amyloid-β positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume

Sánchez‐Benavides, G., Suárez‐Calvet, M., Milà‐Alomà, M., Arenaza‐Urquijo, E. M., Grau‐Rivera, O., Operto, G., Gispert, J. D., Vilor‐Tejedor, N., Sala‐Vila, A., Crous‐Bou, M., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.02.026 · Cited by 22 · see citing works

Central and Peripheral Inflammation in Mild Cognitive Impairment in the Context of Alzheimer’s Disease

Schmidt-Morgenroth, I., Michaud, P., Gasparini, F., & Avraméas, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310523 · Cited by 21 · see citing works

Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer’s Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion

Esquer, A., Blanc, F., & Collongues, N. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00541-1 · Cited by 22 · see citing works

The mediating role of neuroimaging-derived biological brain age in the association between risk factors for dementia and cognitive decline in middle-aged and older individuals without cognitive impairment: a cohort study

Cumplido‐Mayoral, I., Brugulat‐Serrat, A., Sánchez‐Benavides, G., González‐Escalante, A., Anastasi, F., Milà‐Alomà, M., López‐Martos, D., Akinci, M., Falcón, C., Shekari, M., et al. (2024) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(24)00025-4 · Cited by 23 · see citing works

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline

Pelkmans, W., Vromen, E. M., Dicks, E., Scheltens, P., Teunissen, C. E., Barkhof, F., van der Flier, W. M., Tijms, B. M., & Initiative, A. D. N. (2022) · Brain Communications · doi:10.1093/braincomms/fcac026 · Cited by 20 · see citing works

Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit

Johnson, S. C., Suárez‐Calvet, M., Suridjan, I., Minguillón, C., Gispert, J. D., Jonaitis, E. M., Michna, A., Carboni, M., Bittner, T., Rabe, C., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01168-y · Cited by 21 · see citing works

Peripheral sTREM2-Related Inflammatory Activity Alterations in Early-Stage Alzheimer’s Disease

Weber, G. E., Khrestian, M., Tuason, E. D., Shao, Y. Y., Pillai, J. A., Rao, S. M., Feng, H., Zhou, Y., Cheng, F., DeSilva, T. M., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100771 · Cited by 21 · see citing works

CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's disease

Warmenhoven, N., Sánchez‐Benavides, G., González‐Escalante, A., Milà‐Alomà, M., Shekari, M., López‐Martos, D., Ortiz‐Romero, P., Kollmorgen, G., Quijano‐Rubio, C., Minguillón, C., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13862 · Cited by 22 · see citing works

Cerebrospinal Fluid sTREM-2, GFAP, and β-S100 in Symptomatic Sporadic Alzheimer’s Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimer’s Disease Continuum

Bonomi, C. G., Assogna, M., Donna, M. G. D., Bernocchi, F., Lucia, V. D., Nuccetelli, M., Fiorelli, D., Loizzo, S., Mercuri, N. B., Koch, G., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221010 · Cited by 20 · see citing works

Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile

Milà‐Alomà, M., Shekari, M., Salvadó, G., Gispert, J. D., Arenaza‐Urquijo, E. M., Operto, G., Falcón, C., Vilor‐Tejedor, N., Grau‐Rivera, O., Sala‐Vila, A., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00863-y · Cited by 19 · see citing works

Principal components from untargeted cerebrospinal fluid metabolomics associated with Alzheimer's disease biomarkers

Dong, R., Denier‐Fields, D. N., Lu, Q., Suridjan, I., Kollmorgen, G., Wild, N., Betthauser, T. J., Carlsson, C. M., Asthana, S., Johnson, S. C., et al. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.04.009 · Cited by 18 · see citing works

P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles

Wesenhagen, K. E. J., Tijms, B. M., Boonkamp, L., Hoede, P. L., Goossens, J., Dewit, N., Scheltens, P., Vanmechelen, E., Visser, P. J., & Teunissen, C. E. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01038-z · Cited by 18 · see citing works

Differential effects of sleep on brain structure and metabolism at the preclinical stages of AD

Stankeviciute, L. S., Falcón, C., Operto, G., García-Prat, M., Shekari, M., Iranzo, Á., Niñerola‐Baizán, A., Perissinotti, A., Minguillón, C., Fauria, K., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13102 · Cited by 18 · see citing works

Proteomics of the astrocyte secretome reveals changes in their response to soluble oligomeric Aβ

Matafora, V., Gorb, A., Yang, F., Noble, W. J., Bachi, A., Perez‐Nievas, B. G., & Jiménez-Sánchez, M. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15875 · Cited by 18 · see citing works

Inhibition of Pro-Inflammatory Microglia with Minocycline Improves Cognitive and Sleep-Wake Dysfunction Under Respiratory Stress in a Sporadic Model for Alzheimer’s Disease

Vicente, M. C., Paneghini, J. D. L., Stabile, A. M., Amorim, M. R., Silva, C. E. A., Patrone, L. G. A., Cunha, T. M., Bícego, K. C., Almeida, M. C., Carrettiero, D. C., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230151 · Cited by 20 · see citing works

Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium

Sexton, C. E., Solis, M., Aharon‐Peretz, J., Alexopoulos, P., Apostolova, L. G., Bayen, É., Birkenhager, B., Cappa, S. F., Constantinidou, F., Fortea, J., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12588 · Cited by 17 · see citing works

Transcriptome analysis of fasudil treatment in the APPswe/PSEN1dE9 transgenic (APP/PS1) mice model of Alzheimer’s disease

Yan, H., Yan, Y., Gao, Y., Zhang, N., Kumar, G., Fang, Q., Li, Z., Li, J., Zhang, Y., Song, L., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10554-9 · Cited by 17 · see citing works

Genotypic effects of APOE -ε4 on resting-state connectivity in cognitively intact individuals support functional brain compensation

Cacciaglia, R., Operto, G., Falcón, C., Gónzalez‐de‐Echávarri, J. M., Sánchez‐Benavides, G., Brugulat‐Serrat, A., Milà‐Alomà, M., Blennow, K., Zetterberg, H., Molinuevo, J. L., et al. (2022) · Cerebral Cortex · doi:10.1093/cercor/bhac239 · Cited by 17 · see citing works

A fully automated paper-based smartphone-assisted microfluidic chemiluminescence sample to result immunoassay platform

Sun, J., Duan, S., Xu, W., He, W., Li, T., Liu, S., Hoettges, K. F., Zhu, J., Leach, M. P., & Song, P. (2025) · Analytica Chimica Acta · doi:10.1016/j.aca.2025.344013 · Cited by 16 · see citing works

Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer’s disease

Wang, X., Zhang, X., Liu, J., Zhang, J., Liu, C., Cui, Y., Song, Q., Hou, Y., Wang, Y., Zhang, Q., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01440-9 · Cited by 15 · see citing works

Correlations between plasma markers and brain Aβ deposition across the AD continuum: Evidence from SILCODE

Yu, X., Shi, R., Zhou, X., Zhang, M.-K., Cai, Y., Jiang, J.-H., & Han, Y. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14084 · Cited by 15 · see citing works

Longitudinal progression of blood biomarkers reveals a key role of astrocyte reactivity in preclinical Alzheimer’s diseasePreprint

Varma, V., An, Y., Kac, P. R., Bilgel, M., Moghekar, A., Loeffler, T., Amschl, D., Troncoso, J. C., Blennow, K., Zetterberg, H., et al. (2024) · medRxiv · doi:10.1101/2024.01.25.24301779 · Cited by 16 · see citing works

Tau Protein Alterations Induced by Hypobaric Hypoxia Exposure

Pena, E., Martin-Salamanca, R. S., Alam, S. E., Flores, K., & Arriaza, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020889 · Cited by 16 · see citing works

Awareness of episodic memory and meta-cognitive profiles: associations with cerebrospinal fluid biomarkers at the preclinical stage of the Alzheimer’s continuum

López‐Martos, D., Suárez‐Calvet, M., Milà‐Alomà, M., Gispert, J. D., Minguillón, C., Quijano‐Rubio, C., Kollmorgen, G., Zetterberg, H., Blennow, K., Grau‐Rivera, O., et al. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1394460 · Cited by 15 · see citing works

Sleep duration and biomarkers of inflammation in African American and white participants with a parental history of Alzheimer's disease

Pak, V. M., Paul, S., Swieboda, D., Balthazar, M. S., & Wharton, W. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12332 · Cited by 13 · see citing works

Machine learning and deep learning in clinical practice: Advancing neurodegenerative disease diagnosis with multimodal markers

Zarei, O., moghaddam, M. T., & Vastegani, S. M. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111667 · Cited by 17 · see citing works

Differential Effects of APOE and Modifiable Risk Factors on Hippocampal Volume Loss and Memory Decline in Aβ− and Aβ+ Older Adults

Rosenich, E., Bransby, L., Yassi, N., Fripp, J., Laws, S. M., Martins, R. N., Fowler, C. J., Rainey‐Smith, S. R., Rowe, C. C., Masters, C. L., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200118 · Cited by 14 · see citing works

Beyond CSF and Neuroimaging Assessment: Evaluating Plasma miR-145-5p as a Potential Biomarker for Mild Cognitive Impairment and Alzheimer’s Disease

Wen, Q., Wittens, M. M. J., Engelborghs, S., van Herwijnen, M. H. M., Tsamou, M., Roggen, E., Smeets, H. J. M., Krauskopf, J., & Briedé, J. J. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00740 · Cited by 14 · see citing works

P-tau and neurodegeneration mediate the effect of β-amyloid on cognition in non-demented elders

Ma, L., Hu, H., Wang, Z.-T., Ou, Y., Dong, Q., Tan, L., & Yu, J. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00943-z · Cited by 15 · see citing works

Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy

Svenningsson, A. L., Stomrud, E., Palmqvist, S., Hansson, O., & Ossenkoppele, R. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01081-w · Cited by 14 · see citing works

Amyloid‐β, tau, synaptic dysfunction, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimer’s continuum

Suárez‐Calvet, M., Milà‐Alomà, M., Salvadó, G., Gispert, J. D., Vilor‐Tejedor, N., Grau‐Rivera, O., Sala‐Vila, A., Sánchez‐Benavides, G., Arenaza‐Urquijo, E. M., Crous‐Bou, M., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.044444 · Cited by 1 · see citing works

Multiple biological pathways associate with cerebral amyloid load in the early Alzheimer's continuum

Salvadó, G., Molinuevo, J. L., Milà‐Alomà, M., Falcón, C., Operto, G., Cacciaglia, R., Arenaza‐Urquijo, E. M., Vilor‐Tejedor, N., Shekari, M., Minguillón, C., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.044733

CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET

Milà‐Alomà, M., Brinkmalm, A., Ashton, N. J., Kvartsberg, H., Shekari, M., Operto, G., Salvadó, G., Falcón, C., Gispert, J. D., Vilor‐Tejedor, N., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012853 · Cited by 117 · see citing works

Astrocyte biomarkers GFAP and YKL‐40 mediate early Alzheimer's disease progression

Pelkmans, W., Shekari, M., Brugulat‐Serrat, A., Sánchez‐Benavides, G., Minguillón, C., Fauria, K., Molinuevo, J. L., Grau‐Rivera, O., González Escalante, A., Kollmorgen, G., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13450 · Cited by 122 · see citing works

Different astrocyte phenotypes mediate the pathological cascade early in the Alzheimer’s disease continuum

Pelkmans, W., Shekari, M., Brugulat‐Serrat, A., Sánchez‐Benavides, G., Minguillón, C., Fauria, K., Molinuevo, J. L., Grau‐Rivera, O., Escalante, A. G., Kollmorgen, G., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.074674